Loading clinical trials...

Post-Marketing Surveillance of Lenvima in Korean Patients | Clinical Trials | Clareo Health

COMPLETED

Post-Marketing Surveillance of Lenvima in Korean Patients

NCT02764554•Eisai Korea Inc.

Summary

The purpose of this post-marketing surveillance (PMS) is to observe the safety profile of Lenvima (lenvatinib) in normal clinical practice setting.

Eligibility

Age

All ages

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Participants who meet the following criteria will be eligible for inclusion in the study:
•1. Participants with approved indication for lenvatinib in Korea
•2. Participants who have written consent for use of personal and medical information for the study purpose

Locations (32)

Eisai Trial Site #18

Anyang, Gyeongji-do, South Korea

Eisai Trial Site #30

Bundang, Gyeongji-do, South Korea

Eisai Trial Site #14

Goyang, Gyeongji-do, South Korea

Eisai Trial Site #27

Goyang, Gyeongji-do, South Korea

Eisai Trial Site #34

Goyang, Gyeongji-do, South Korea

Eisai Trial Site #21

Suwon, Gyeongji-do, South Korea

Eisai Trial Site #24

Yangsan, Gyeongsangnam-do, South Korea

Eisai Trial Site #15

Busan, South Korea

Eisai Trial Site #16

Busan, South Korea

Eisai Trial Site #17

Busan, South Korea

Key Dates

Start Date

November 10, 2016

Primary Completion Date

September 29, 2021

Completion Date

September 29, 2021

Last Updated

October 7, 2021

Enrollment

132

ACTUAL participants

Conditions

Differentiated Thyroid Carcinoma (DTC)